A new study jointly conducted by Oregon State University College of Veterinary Medicine and the Oregon Health & Science University Cancer Institute may one day help both canines and humans with this form of cancer.
Brian Druker, M.D., director of the OHSU Cancer Institute who discovered the targeted therapy drug Gleevec for chronic myeloid leukemia (CML), is teaming up with OSU veterinary oncologist and researcher Stuart Helfand, D.V.M. Dr. Helfand was one of the first to discover abnormalities in hemangiosarcoma growth pathways similar to those responsible for CML in humans.
Hemangiosarcomas strike all dog breeds, but is more often noted in German Shepherds and Golden Retrievers. It is a rapidly growing, highly invasive cancer. Thanks to this grant, the Druker Laboratory is now studying a cell line developed in Helfand’s laboratory from a German Shepherd that died of this sarcoma. The researchers want to see what drugs can be developed to treat this disease. In turn, this research may ultimately benefit people with similar cancers.